Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA | Optometry Times - Clinical News

Published on December 17, 2025
K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.
Continue reading on website
Other news

Canadian Association of Optometrists Appoints Joelle Walker as New CEO

December 17, 2025
OTTAWA, Ontario—The Canadian Association of Optometrists (CAO) has announced that Joelle Walker will assume the role of chief executive officer (CEO), effective January 19, 2026. Walker will replace François Couillard, CAO’s current CEO, who will retire at the end of 2025 after a career spanning more than 40 years, the announcement noted. Reporting to the CAO Council, Walker will be responsible fo

NEI scientists use retinal connectomics to study color vision circuitry relevant for mood, myopia

December 17, 2025
NEI scientists constructed a 3D map of the neural circuitry of S-cone photoreceptors, important for perceiving blue light